B&L to use Santen polymers for lenses
This article was originally published in Clinica
In a bid to develop next-generation intraocular lenses (IOLs), Bausch & Lomb has signed a licensing agreement for Santen Pharmaceutical’s foldable hydrophobic acrylic polymers. The deal sees B&L (Aliso Viejo, California) gain the right to use the CE-marked and FDA-approved polymers to develop and commercialise IOLs on a global basis, except for Japan, where Osaka-based Santen will retain the exclusive rights. As well as using the polymers to develop new IOLs, which are used to replace cataractous lenses, B&L said that the materials would be complementary to its existing Crystalens, Akreos and SoftPort products. Financial terms of the deal were not revealed.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals